Remove 2025 Remove Pharmacy Remove Regulations
article thumbnail

Florida Seeks Patient Prescription Data

Drugs.com

THURSDAY, March 6, 2025 -- Florida’s insurance regulator is demanding detailed prescription data on millions of patients, raising alarms over patient privacy. In January, the Florida Office of Insurance Regulation asked pharmacy benefit.

Pharmacy 288
article thumbnail

What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar)

Drug Channels

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: Whats Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. It is part of The Drug Channels 2025 Video Webinar Series.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PBM Industry Update: Trends, Challenges, and What's Ahead (NEW Live Video Webinar)

Drug Channels

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: PBM Industry Update: Trends, Challenges, and What's Ahead This event will be broadcast live on Friday, April 4, 2025, from 12:00 p.m. This event is part of The Drug Channels 2025 Video Webinar Series.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

As pharma companies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces. These markets are characterized by stringent pricing regulations and decentralized healthcare systems, making localized sales expertise essential.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Multimodality however can detect and connect trends (and in future generate content) across different modalities and therefore allows for better interpretability, which builds trust between regulators, researchers and industry stakeholders. The Rise of Multimodal Language Models in Drug Development (2025).

Drugs 64
article thumbnail

Article FDA Thank You Addressing benzene contamination, FDA issues guidance for reformulating products containing certain carbomers

Agency IQ

For regulators, there are two primary concerns associated with impurities – that they may cause a drug substance to degrade (thereby reducing its efficacy or safety) and that the impurities (or their effects on the drug substance) may be harmful to patients. Read AgencyIQ’s analysis of the ICH guideline here ].

FDA 40
article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. This study is planned to start in late 2024 and conclude in late 2025.

FDA 40